Please assess the completion status of the following clinical trial:

Trial Title: S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Distant metastatic disease confirmed by histology, cytology, or strong clinical evidence~* Measurable disease~* No known brain or CNS metastases~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 70 and over OR~* Under 60~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Hemoglobin at least 9 g/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* SGOT or SGPT no greater than 1.5 times ULN (2.0 times ULN if liver metastases are present)~* Alkaline phosphatase no greater than 1.5 times ULN (2.0 times ULN if liver metastases are present)~Renal:~* Creatinine no greater than ULN~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy for breast cancer~Chemotherapy:~* Prior adjuvant or neoadjuvant chemotherapy allowed~* Prior adjuvant taxanes allowed~* No other concurrent chemotherapy for breast cancer~Endocrine therapy:~* Prior hormonal therapy in the adjuvant setting or for metastatic disease allowed~* No concurrent hormonal therapy for breast cancer~Radiotherapy:~* No concurrent radiotherapy for breast cancer~Surgery:~* Not specified~Other~* No more than 1 prior regimen for advanced, recurrent, or metastatic disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- docetaxel (Type: EXPERIMENTAL): docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).